{"organizations": [], "uuid": "68b14bd71faeb4d3d905ab294de96f0dba81e500", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-astrazeneca-announces-renewed-us-r/brief-astrazeneca-announces-renewed-u-s-recommendation-availability-of-flumist-quadrivalent-vaccine-idUSFWN1QB10R", "country": "US", "domain_rank": 408, "title": "BRIEF-Astrazeneca Announces Renewed U.S. Recommendation, Availability Of Flumist Quadrivalent Vaccine", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T22:41:00.000+02:00", "replies_count": 0, "uuid": "68b14bd71faeb4d3d905ab294de96f0dba81e500"}, "author": "", "url": "https://www.reuters.com/article/brief-astrazeneca-announces-renewed-us-r/brief-astrazeneca-announces-renewed-u-s-recommendation-availability-of-flumist-quadrivalent-vaccine-idUSFWN1QB10R", "ord_in_thread": 0, "title": "BRIEF-Astrazeneca Announces Renewed U.S. Recommendation, Availability Of Flumist Quadrivalent Vaccine", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s. recomm", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "astrazeneca plc", "sentiment": "none"}, {"name": "availability of flumist quadrivalent vaccine reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 8:42 PM / Updated 15 minutes ago BRIEF-Astrazeneca Announces Renewed U.S. Recommendation, Availability Of Flumist Quadrivalent Vaccine Reuters Staff Feb 21 (Reuters) - AstraZeneca PLC: * ASTRAZENECA ANNOUNCES RENEWED RECOMMENDATION AND AVAILABILITY OF FLUMIST QUADRIVALENT VACCINE IN THE US * ASTRAZENECA - RESULTS DEMONSTRATED NEW 2017-2018 H1N1 LAIV POST-PANDEMIC STRAIN PERFORMED BETTER THAN 2015-2016 H1N1 LAIV POST-PANDEMIC STRAIN​ * ASTRAZENECA - CDC‘S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VOTED IN FAVOR OF RENEWED RECOMMENDATION FOR FLUMIST QUADRIVALENT USE IN U.S. 2018-2019 SEASON Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T22:41:00.000+02:00", "crawled": "2018-02-21T23:06:15.050+02:00", "highlightTitle": ""}